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appear to be a factor. However, the incidence of RVO clearly 
is dependent upon age with prevalence ranging from 0.3(40-
49 years old) to 5.6 (80-100 years) [2]. Why there are these 
differences with race and age is, again, not known.
Although the pathogenesis of RVO remains to be nebulous, 
it has been hypothesized that its origin is probably related to 
hemodynamic changes (e.g., venous stasis), degenerative changes 
of the vascular walls, and blood hyper coagualibility [3,4,5 ]. Risk 
factors for RVO include hypertension, arteriosclerosis, diabetes 
mellitus (DM), hyperlipidemia, stroke, blood viscosity, and 
thrombophilia [3]. Cigarette smoking also enhances the risk of 
RVO as do systemic inflammatory conditions, and glaucoma [3, 
6]. In addition, preeclampsia in women also appears to pose 
an increased risk for development of RVO [7].  Browning in his 
compendium has stated that “the patho physiology of retinal 
vein occlusion consists of three components of Virchow’s triad- 
abnormalities of the vessel wall, alterations in the blood (e.g., 
abnormalities of viscosity and coagulation), and alterations in 
blood flow” [8]. Is there a common factor(s) underlying all of 
these diverse risk factors?
Over the past 35 years, a considerable body of evidence has 
been brought forth which clearly indicates that all of the above 
risk factors for development of RVO including age, race, vascular 
changes, blood coagulability , arteriosclerosis, DM, stroke, 
systemic  inflammatory conditions , hypertension, glaucoma, 
macular edema, vitreous hemorrhage, retinitis pigmentosa,  and 
preeclampsia have been associated with deficient (mgD) states, 
both experimentally in animals and in human subjects [ e.g., see 
9- 19].
Abstract
Although numerous hypotheses (and potential risk factors), have 
been offered to explain the origins and potential mechanism(s) for 
central retinal vein occlusion (RVO) in patients of diverse ages, there 
is no agreement. Recently, considerable epidemiological evidence 
has been brought forth which indicates a strong association between 
RVO, myocardial infarctions, heart failure, and stroke. Magnesium 
(Mg) deficiency (mgD) has long-been associated with glaucoma and 
diabetic retinopathy. Over the past three decades, our laboratories 
have found strong associations of mgD linked to morbidity/
mortality in cardiovascular diseases such as myocardial infarctions, 
cardiac failure, atherogenesis, and strokes, both experimentally and 
clinically. More recently, we have reported direct links of mgD in 
these disease syndromes with generation and release of ceramides 
and platelet-activating factor (PAF). In this report, we present a novel 
hypothesis for a probable underlying mgD and release of ceramides 
and PAF as causal factors in development and progression of RVO. 
We believe this hypothesis could prove useful in the diagnosis and 
treatment of RVO
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Introduction
A number of epidemiologic studies from around the world 
suggest a growing relationship between retinal vein occlusion 
(RVO), myocardial infarction, and mortality which is unexplained 
[for recent review, see 1]. Depending upon geographic region, 
age, and race the incidence varies between 2.8 per 1000(white 
Caucasians) and 6.9 per 1000 (Hispanics) with blacks in between 
(i.e., 3.9 per 1000) [see 2, for recent review). Gender does not 
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 Magnesium Deficiency and Glaucoma
Glaucoma is an eye condition characterized by a chronic 
neuropathy causing vision loss. Elevated intraocular pressure 
(IOP) is known to be a major risk factor for development of 
glaucoma. But, this risk factor, in itself, does not appear to 
adequately explain the course of the disease [20]. Most of the 
individuals showing increased IOP do not develop glaucoma; 
interestingly approximately one-half of the patients with 
glaucomatous optic neuropathy show IOP’s in the normal 
range [21]. Thus, it has become obvious that factors (unknown) 
,other than elevated IOP, must perforce be important factors in 
development of glaucoma. Alterations in ocular blood flows and 
oxidative stresses have been suggested as causal factors [20,21]. 
Mg has been shown to increase ocular blood flow in patients 
with glaucoma and appears to have protective attributes against 
oxidative stresses and apoptosis [15].  Using rats, it has been 
demonstrated that dietary Mg deficiency can result in necrosis 
of the retinal pigment epithelium [10]. Multifocal necrosis and 
myelination disturbances have been noted in the optic nerve [16]. 
Moreover, using dietary Mg deficiency, in rats, it has been reported 
that the numbers of microvilli in the corneal epithelial and 
endothelial cells were decreased in number [17].  Interestingly, 
Mg taurate has been found to alter the progression of cataracts 
in some patients [22]. In addition, it has long been known that 
patients with diabetes (types 1 and 2), have often low serum total 
Mg levels [23,24,25 ]. We have shown that the physiologically, 
important ionized level of Mg2+ is clearly reduced in both blood 
and red blood cells in diabetes [24-28].  Our laboratories, almost 
35 years ago, first demonstrated that low extracellular Mg2= 
levels result in decreased cerebral blood flows. Subsequently, we 
found  that low [Mg2+]0 resulted   in reductions in cellular free 
Mg and vasospasm of cerebral blood vessels as well as oxidative 
stress, DNA damage,  induction of nuclear factor-KB,  induction of 
proto-oncogenes c-fos and c-jun, down regulation of telomerase 
activity,  and apoptosis of cerebral vascular smooth muscles in 
primary cultures [30-41]. Working with aged glaucoma patients 
(65-82 years old),  and 31P-NMR spectroscopy and ion-selective 
electrodes,  we found the serum ionized Mg level as well as the 
red blood cell Mg2+ level to be significantly reduced ( e.g., serum 
: 0.55 vs. 0.66 mm in aged-matched controls; p<0.001) [ Resnick, 
Altura, Altura, 1995, unpublished data] . The significance of our 
findings are discussed in detail, below, in the remaining sections 
of this report.
Magnesium, Mg Deficiency, Diet, Vasospasm, and 
Cardiovascular Pathobiology
Disturbances in diet are known to promote lipid deposition 
and accelerate the growth and transformation of smooth muscle 
cells in the vascular walls and to promote cardiac dysfunction 
[33,35,39,42-46]. Major risk factors in development of RVO are 
atherosclerotic changes , endothelial damage ,hypertension, 
and thrombus formation (as stated above) as well as increased 
growth of microscopic blood vessels in the retina; all of these 
can be inhibited/ameliorated by adequate Mg levels [15,22,24-
28,33,34, 40-47 ]. Several epidemiologic studies in North America 
and Europe have shown that people consuming Western-type 
diets are low in Mg content( i.e., 30-65% of the RDA for Mg 
[40,44-46, 48-50]); most such diets in the U.S.A. show that 60-
80% of Americans are consuming185-235 mg/day of Mg [40,44-
46,48-50 ].  The elderly(who demonstrate the highest risk for 
RVO)  exhibit the lowest levels of magnesium intake worldwide. 
In 1900, Americans were consuming about 450-550 mg/day 
[35,40]. Low Mg content of drinking water, found in areas of 
soft-water and Mg-poor soil, is associated with high incidences 
of atherosclerosis, hypertension, thrombosis, ischemic heart 
disease (IHD), coronary vasospasm, and sudden cardiac death 
(SCD) [33,40,51-55]. Both animal and human studies have 
shown an inverse relationship between dietary intake of Mg and 
atherosclerosis [33,35,40, 56,57]. The myocardial level of Mg has 
consistently been observed to be lower in subjects dying from 
IHD and SCD in soft-water areas than those living in hard-water 
areas [33,35,40,43-45,51-55]. More than 45 years ago, two of 
us demonstrated that Mg2+behaves as a natural calcium channel 
blocker in both cardiac and vascular smooth muscle (VSM) 
cells [31,33,35,40,58-67 ].  We also showed that Mg behaves 
as a natural statin in that it can lower both cholesterol and 
triglyceride levels [43] as well as act as a powerful vasodilator in 
the microcirculation [67-70] , on coronary arteries [33,65,66,71-
79], as well as on cerebral blood vessels[29,32-34 ], and as a 
cardiac muscle relaxant [33-35,65,75-77]. Hypermagnesemic 
diets have been shown to ameliorate hypertension, diabetes 
mellitus, atherosclerosis, thrombosis, hypercoagulability, 
strokes, myocardial infarctions, and preeclampsia-eclampsia; all 
conditions associated with RVO [28,33-35,40,42-46,56,57,65,80-
88 ]. Using sensitive and newly-designed, specific Mg2+-ion 
selective electrodes, our laboratories showed that patients with 
hypertension, IHD, cardiac failure, strokes, diabetes mellitus 
types I and 2 ,atherosclerosis, myocardial infarctions, aging, and 
preeclampsia-eclampsia, and women with diverse cardiovascular 
disturbances exhibit significant reductions in serum/plasma/
whole blood levels of ionized but not necessarily total, blood 
levels of Mg[24-28,34-37,40,89-107 ].  In addition, using 31P- 
NMR spectroscopy, we demonstrated that a number of patients 
with these cardiovascular-disease syndromes exhibit lowered 
Mg2+ levels in red blood cells [25-27,106,107].  Our group has also 
shown that dietary deficiencies of Mg in rats and rabbits causes 
vascular remodeling (i.e., arteriolar wall hypertrophy, increased 
capillary growth, and alterations in the matrices of the vascular 
walls) concomitant with atherogenesis, elevated blood pressure 
and micro vascular vasospasm [33,35,40,43,47,108-111 ]; these 
microvessel changes being in many respects similar to what 
happens in the retinas of RVO -victims. 
Approximately 45 years ago, two of us reported that declining 
levels of extracellular Mg2+ ([Mg2+]0 ) in isolated arteries and 
arterioles resulted in concentration-dependent constriction and 
vasospasm [58,59 ] . These phenomena were noted, subsequently, 
in vitro and in vivo, in cerebral, coronary, umbilical -placental, and 
splanchnic blood vessels [29-37,39,40,60-66,70-74, 76,77,108-
112 ]. These low [Mg2+] 0-induced vasospasms could only be 
attenuated or inhibited with elevated concentrations of Mg2+. In 
addition, we noted that small venous vessel (i.e., 60-100um o.d.) 
vasospasm, induced by low [Mg2+] 0 , would often result in rupture 
Page 3 of 9Citation: Altura BM, Gebrewold A, Shah NC, Zhang A, Li W, et al. (2017) Why is there an Association between Retinal Vein Occlusion, 
Vision Loss, Myocardial Infarction, Stroke and Mortality: Potential Roles of Hypomagnesaemia, Release of Sphingolipids, and Platelet-
Activating Factor. Int J Open Access Clin Trials  2(1): 9. 
Why is there an Association between Retinal Vein Occlusion, Vision 
Loss, Myocardial Infarction, Stroke and Mortality: Potential Roles of 
Hypomagnesaemia, Release of Sphingolipids, and Platelet-Activating Factor
Copyright: 
© 2017 Altura et al.
of post capillary  venules (i.e., 35-55 um o.d.) with extravasations 
of blood and formed elements into the surrounding brain tissues 
,as observed by direct in -situ TV microscopic studies on the 
intact cerebral microcirculation in the living brains of rats [32-
35,47,87,110 ]; these inflammatory responses are ,thus,  very 
similar to what is observed in patients with RVO. Ever since 
our early findings on the intact brain and coronary tree were 
published [58,59], a number of clinical studies on the hearts 
of diseased patients have been published which support our 
hypothesis [113-116]. Using intact rats subjected to Mg deficient 
diets (MDD) , and employing  31P-nuclear magnetic resonance 
spectroscopy (31P-NMR) , and optical-reflectance spectroscopy 
[34,35,40,41,77,78,117], we have noted that low levels of dietary 
Mg intake result in reductions in cerebral blood flows, reduction 
in cerebral and VSM [Mg2+]i, reduced levels of ATP, increased 
cellular levels of inorganic phosphate, reduced cellular  levels 
of intracellular pH, generation of powerful reactive oxygen and 
nitrogen species,  [Ca2+]i  overload, and reduction in mitochondrial 
levels of cytochrome oxidase , thus resulting in hypoxic states 
. Since the retinal circulation is, physiologically, in many ways, 
similar to the cerebral circulation [8] , we believe that the 
characteristic changes seen in the retinas of RVO patients[for 
review, see 8 ] may perforce be due , in part, to a Mg deficiency. 
However, since 1997 we have found dramatic evidence that MDD 
results in inflammatory-like conditions,  activation of multiple 
enzymatic pathways which result in formation of sphingolipids 
(e.g., ceramide, sphingosine, spingosine-1-phosphate,etc) , 
and synthesis and release of platelet-activating factor(PAF) 
[41,87,88,118-128 ].
Low Mg2+, Increased Adhesiveness to Venular Endo-
thelial Walls, Increased Post capillary Permeability 
and Vasoconstriction in the Microcirculation: Relation 
to Inflammatory Reactions
Inflammation usually is defined as a response of 
microcirculatory blood vessels and the tissues they perfuse 
to infections and damaged tissues which bring cells and host-
defense factors /molecules directly from the circulation to all 
the diverse sites where they are required, in order to eliminate/
degrade all the offending agents [129,130]. The mediators of the 
innate -defense mechanisms include white blood cells, phagocytic 
leukocytes, monocytes, macrophages, antibodies, and cytokines, 
chemokines, and complement proteins. The inflammatory 
process brings these cells and molecules to the damaged or 
necrotic tissues. Such events are observed in patients with RVO 
[for review, see 8]. During the normal inflammatory process, 
leukocytes, macrophages, and monocytes migrate across the 
venous capillary walls through gaps between the endothelial 
cells, due to increases in permeability and move to the site(s) of 
injury via chemotaxis [129,130] . The normal mediators for these 
processes to take place are: adhesion molecules; and cytokines 
and chemokines [129,130]. Interestingly, we have found in 
diverse microcirculatory beds of rats and mice, fed low dietary 
Mg intake, increased adhesiveness of leukocytes, monocytes, and 
platelets to the venular walls coupled with vasoconstriction/
spasm and increased postcapillary venular permeability [127, 
unpublished findings]; obviously, these phenomena are clear 
signs of inflammatory responses and have been observed in 
retinas of patients with RVO [8]. Toll-like receptor-mediated 
(TLRM) pathways appear to be activated in the MDD animals 
[15, 22]. We have found that these TLRM pathways are activated 
through nuclear-factor kappa B (NF-KB) in MDD and seem to take 
place early in the Mg deficient tissues [unpublished findings]. 
Whether similar phenomena take place in patients’ retinas 
presenting with RVO remains to be seen. 
Mg2+Regulates Sphingolipid Pathways in Cerebral and 
Coronary Vascular Smooth Muscle Cells: Potential Im-
pact in Patients with RVO
Recent studies from our laboratories, over the past two 
decades, indicate that Mg2+ ions can modulate sphingolipid 
pathways in a variety of VSM and cardiac cell types, including 
coronary and cerebral VSM [40,41,87,118-126]. One of 
these byproducts is ceramide.  Ceramides are sphingolipids 
known to be released as a consequence of sphingomyelinases 
(smases) acting on sphingomyelin (SM), a component of all 
cell membranes(external and internal), or as a consequence of 
activation of serine palmitoyl transferase 1 and 2(SPT 1 and 
SPPT 2)( a synthetic pathway) [131,132 ], activation of ceramide 
synthase,  or a “salvage pathway” [126 ] . Ceramides are now 
thought to play important roles in fundamental processes such as 
inflammation, angiogenesis, atherogenesis, membrane-receptor 
functions, cell proliferation, microcirculatory blood flows, cell 
adhesion, immunogenic responses, and apoptosis, among others 
[ for recent review, see 133  ] . Note that all of these functions/
characteristics are not only found in MDD animals, but also in 
patients with RVO. It is of considerable interest to note, here, 
that, experimentally, myocardial infarctions have been shown 
to be associated with rising levels of ceramides [134,135].  In 
human subjects, it has been reported that stable angina pectoris, 
unstable angina pectoris, and acute myocardial infarction are 
also associated with rising levels of ceramides [136,137]. In 
some of these patients, a clear elevation in smases was observed 
[136]. Although such studies have not, to our knowledge, been 
undertaken in patients presenting with RVO, we suspect, when 
looked for, this will be the case, along with Mg2+ deficiency.
Mg2+-Deficient Environments Lead to Formation of 
PAF: Potential Significance to RVO
PAF is known to play major roles in both inflammatory 
reactions and atherogenesis [138-140]. A variety of the 
circulating blood-formed elements ( e.g., polymorph nuclear 
leukocytes, platelets, basophils, and macrophages ) as well as 
endothelial cells can elaborate PAF [139,140 ]. We have, very 
recently, demonstrated that cerebral, aortic and coronary 
VSM cells can also elaborate and release PAF [87,127].  There 
are some reports that both PAF and ceramides may result in 
transformation of VSM cells from one phenotype to another, as 
is typical in the atherosclerotic process [139,140 ]. In addition, 
like we have observed in MDD, PAF produces vasoconstriction of 
blood vessels in a variety of VSM cell types [ for recent review, see 
127] , as do several of the ceramides [141, unpublished findings 
Page 4 of 9Citation: Altura BM, Gebrewold A, Shah NC, Zhang A, Li W, et al. (2017) Why is there an Association between Retinal Vein Occlusion, 
Vision Loss, Myocardial Infarction, Stroke and Mortality: Potential Roles of Hypomagnesaemia, Release of Sphingolipids, and Platelet-
Activating Factor. Int J Open Access Clin Trials  2(1): 9. 
Why is there an Association between Retinal Vein Occlusion, Vision 
Loss, Myocardial Infarction, Stroke and Mortality: Potential Roles of 
Hypomagnesaemia, Release of Sphingolipids, and Platelet-Activating Factor
Copyright: 
© 2017 Altura et al.
].  A number of investigators , employing intravital microscopy 
techniques, similar to those used by our laboratories [142-
145 ], have demonstrated that PAF increased the number of 
white blood cells in the microvessels concomitant with intense 
vasoconstriction-spasms with increasing concentrations of the 
putative lipid mediator (i.e., PAF), less leukocyte rolling on the 
endothelial cell walls, and increased adherence of the leukocytes 
to the endothelial surfaces with increases in venular-capillary 
permeability . Using open and closed chambers implanted in 
rodent cerebral cortex and skeletal muscles, as mentioned above, 
we have observed similar phenomena [87,127, unpublished 
finings  ]. Furthermore, we have reported that a variety of 
ceramides produce similar microcirculatory actions in rodent 
cerebral, cutaneous and skeletal microvascular tissues, including 
increased permeability of the post capillary walls, the major 
sites of inflammatory reactions [141, unpublished findings ]. 
Collectively, these in-vivo microcirculatory findings strongly 
support our hypothesis that both PAF and ceramides induce 
similar, true inflammatory responses in diverse vascular beds 
in diverse mammalian species. Added to this are some very 
recent findings of Moschos et al [146] on diabetic patients 
with retinopathy who demonstrated increased serum levels 
of platelet-activating factor acetylhydrolase, the enzyme that 
produces PAF; the greater the degree of diabetic retinopathy, 
the more advanced was the disease[146].  We believe similar 
findings will be found in RVO patients when looked for.
Future Considerations, Challenges, and New Thera-
peutic Approaches to RVO
Although the exact underlying cause(s) of RVO in patients 
remains to be determined, a number of magnesium-deficient 
animal models (e.g., with glaucoma; diabetes mellitus 
retinopathy) have been utilized to gain insights into possible 
causes of retinopathy and AMD . Potential  use of knock-out and 
knock-down mice models of these diseases found in Mg-deficient 
animals could be used to determine changes in the genomes( 
due to genotoxic effects)[47 ].  Patients with RVO should be 
examined for lowered blood and red blood cell levels of ionized 
Mg using newly-designed Mg2+-ion selective electrodes and 
31PNMR spectroscopy. From the above evidence and discussion, it 
would be judicious to examine RVO-patients for increased levels 
of ceramides and PAF.
Clinical studies should be undertaken to determine any 
correlations between the course of RVO development and levels 
of ionized Mg, ceramides, and PAF. Moreover if such correlations 
are found, it would probably be prudent to supplement RVO 
patients with Mg. In addition, it probably would be prudent to 
determine in double-blind trials whether use of inhibitors of 
ceramide and PAF generation and release change/benefit the 
course of the disease along with administration of Mg. Only time 
will tell whether these animal studies , human studies and clinical 
trials will prove to validate our hypothesis.
Since we have found in both rats and rabbits, fed low Mg 
diets, that increased levels of both ceramides and PAF are found , 
in situ, in all chambers of the heart, and in cerebral, coronary, and 
peripheral blood vessels, and these cardiac as well as blood vessel 
dysfunctions were associated with decreased serum an tissue 
levels of Mg2+, increased plaques, elevated serum cholesterol, 
elevated triglycerides, elevated ceramides, and increased 
generation of PAF [ e.g., see 87,127  ], we believe it is highly unlikely 
that these in-vivo manifestations are merely epiphenomena. It 
is more than likely that these alterations underlie some of the 
causes of RVO and could serve as underpinnings for more precise 
therapy of RVO in the near future.
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